S. Saraf

L. Sequist, H. Borghaei, S. Jalal, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Preliminary results for the advanced salivary gland carcinoma cohort of the phase 1b KEYNOTE-028 study of pembrolizumab.

J. Gilbert, D. Day, S. Piha-Paul, 2016 .

315O_PRAntitumor activity and safety of pembrolizumab in patients with PD-L1-positive nasopharyngeal carcinoma: Interim results from a phase 1b study

Chiun Hsu, A. Hansen, R. Cohen, 2015 .

Brief Report: Long-Term Overall Survival From KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non-Small-Cell Lung Cancer.

L. Sequist, H. Borghaei, S. Jalal, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal

K. Emancipator, P. Ott, E. Chan, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Effect of palonosetron (5HT-3 antagonist) and pantoprazole (proton pump inhibitor) against surgical esophagitis induced by forestomach and pylorus ligation in albino rats

S. Saraf, S. Saraf, G. Kaithwas, 2016, Human & experimental toxicology.

OA05.01 Pembrolizumab in Patients with Extensive-Stage Small Cell Lung Cancer: Updated Survival Results from KEYNOTE-028

E. Felip, P. Ott, Dong-Wan Kim, 2017 .

Pembrolizumab monotherapy versus chemotherapy in platinum-pretreated, recurrent or metastatic nasopharyngeal cancer (KEYNOTE-122): an open-label, randomized, phase III trial.

R. Swaby, N. Ngamphaiboon, V. Sriuranpong, 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

Pembrolizumab for patients with advanced prostate adenocarcinoma: Preliminary results from the KEYNOTE-028 study

P. Ott, Juanita Lopez, S. Piha-Paul, 2016 .

Pembrolizumab in patients with advanced cervical squamous cell cancer: Preliminary results from the phase Ib KEYNOTE-028 study.

H. Rugo, P. Ott, S. Piha-Paul, 2016 .

Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer

S. Loi, V. Karantza, H. Rugo, 2018, Clinical Cancer Research.

ATIM-35. RESULTS OF THE PHASE IB KEYNOTE-028 MULTI-COHORT TRIAL OF PEMBROLIZUMAB MONOTHERAPY IN PATIENTS WITH RECURRENT PD-L1-POSITIVE GLIOBLASTOMA MULTIFORME (GBM)

K. Tamura, A. Santoro, J. Soria, 2016 .

Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results From the KEYNOTE-028 Study.

H. Rugo, Y. Bang, I. Puzanov, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1-Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial.

H. Rugo, P. Ott, S. Piha-Paul, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety and Antitumor Activity of the Anti-Programmed Death-1 Antibody Pembrolizumab in Patients With Advanced Esophageal Carcinoma.

J. Lunceford, S. Jalal, S. Piha-Paul, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pembrolizumab in Combination With Erlotinib or Gefitinib as First‐Line Therapy for Advanced NSCLC With Sensitizing EGFR Mutation

L. Sequist, A. Patnaik, J. Yang, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Pembrolizumab in combination with ipilimumab as second-line or later therapy for advanced non-small-cell lung cancer: KEYNOTE-021 cohorts D and H.

L. Sequist, H. Borghaei, S. Jalal, 2019, Lung cancer.

Pembrolizumab and platinum-based chemotherapy as first-line therapy for advanced non-small-cell lung cancer: Phase 1 cohorts from the KEYNOTE-021 study.

L. Sequist, H. Borghaei, A. Patnaik, 2018, Lung cancer.

Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma

A. Santoro, S. Piha-Paul, R. Cohen, 2017, PloS one.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, Brian D. Kelly, 2016, Journal of Immunotherapy for Cancer.

Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1-Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study.

Chiun Hsu, A. Hansen, Se-Hoon Lee, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abstract CT178: Olaparib plus pembrolizumab in patients with previously treated advanced solid tumors with homologous recombination repair mutation (HRRm) and/or homologous recombination deficiency (HRD): Initial results of the phase 2 KEYLYNK-007 study

H. Gómez, R. Cristescu, T. Ciuleanu, 2021, Clinical Trials.